Abiomed (ABMD) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
50-Day Range
52-Week Range
258 shs
Average Volume
611,028 shs
Market Capitalization
$17.18 billion
P/E Ratio
Dividend Yield
Price Target
ABMD stock logo

About Abiomed Stock (NASDAQ:ABMD)

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts. As of December 22, 2022, Abiomed, Inc. operates as a subsidiary of Johnson & Johnson.

ABMD Stock News Headlines

FDA warns Abiomed over device classification
This Big Pharma Stock Is a Clear Buy in 2023
3 Powerhouse Stocks to Buy in 2023
3 S&P 500 Stocks to Buy If You Like Winning
3 Reasons to Retain Abiomed (ABMD) Stock in Your Portfolio
10 Best Performing Stocks in November
This Monster Dividend Stock Isn't Done Growing
See More Headlines
Receive ABMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Abiomed and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Fiscal Year End

Industry, Sector and Symbol

Surgical & medical instruments
Health Care Equipment
Current Symbol
Year Founded


Net Income
$136.51 million
Pretax Margin


Sales & Book Value

Annual Sales
$1.03 billion
Cash Flow
$5.09 per share
Book Value
$33.03 per share


Free Float
Market Cap
$17.18 billion

Social Links

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

ABMD Stock Analysis - Frequently Asked Questions

How were Abiomed's earnings last quarter?

Abiomed, Inc. (NASDAQ:ABMD) posted its earnings results on Wednesday, October, 27th. The medical equipment provider reported $1.03 EPS for the quarter, beating analysts' consensus estimates of $0.98 by $0.05. The medical equipment provider had revenue of $248.10 million for the quarter, compared to the consensus estimate of $248.06 million. Abiomed had a net margin of 24.84% and a trailing twelve-month return on equity of 14.77%. The company's revenue for the quarter was up 18.3% on a year-over-year basis. During the same quarter last year, the firm posted $1.01 EPS.
Read the conference call transcript

What is Michael R. Minogue's approval rating as Abiomed's CEO?

96 employees have rated Abiomed Chief Executive Officer Michael R. Minogue on Michael R. Minogue has an approval rating of 72% among the company's employees.

What other stocks do shareholders of Abiomed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Abiomed investors own include NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Align Technology (ALGN), Arista Networks (ANET), Intuitive Surgical (ISRG), Block (SQ), Netflix (NFLX), Adobe (ADBE) and Salesforce (CRM).

Does Abiomed have any subsidiaries?
The following companies are subsidiares of Abiomed: ABD Holding Company, ABIOMED Athlone Ltd, ABIOMED Australia Pte. Ltd, ABIOMED Europe, ABIOMED Japan KK, ABIOMED Limited, ABIOMED R&D, ABIOMED SARL, ABIOMED Singapore Pte. Ltd, AIS GmbH Aachen Innovative Solutions, ECP Entwicklungsgesellschaft mbH, and Impella Cardiosystems.
Read More
This page (NASDAQ:ABMD) was last updated on 5/19/2024 by Staff

From Our Partners